Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
42 hedge funds and large institutions have $204M invested in Unity Biotechnology in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 20 increasing their positions, 4 reducing their positions, and 7 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 4
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
9% more capital invested
Capital invested by funds: $188M → $204M (+$16.5M)
2% more funds holding
Funds holding: 41 → 42 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.01% less ownership
Funds ownership: 3.03% → 3.01% (-0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$13.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.86M |
| 3 |
BlackRock
New York
|
+$1.83M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.42M |
| 5 |
Morgan Stanley
New York
|
+$1.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$11.7M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$3.77M |
| 3 |
AG
Artal Group
Luxembourg
|
-$2.47M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$1.93M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.14M |
UBX Hedge Fund Activity: Q3 2018 in Review
42 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q3 2018, worth a combined $204M — up 8.8% from $188M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new UBX positions and 7 closed out — a net gain of 1 holder — while 20 added to existing stakes and 4 trimmed.
The largest buyer was Capital World Investors, adding an estimated $13.4M. The largest seller was EcoR1 Capital, cutting an estimated $11.7M.
- 42 institutional investors held Unity Biotechnology (UBX) as of Q3 2018, up from 41 in Q2 2018.
- Funds reported $204M of Unity Biotechnology stock for Q3 2018, up 8.8% quarter-over-quarter.
- 8 funds opened new Unity Biotechnology positions in Q3 2018 and 7 closed out, a net change of +1 holder.
- The largest Unity Biotechnology buyer in Q3 2018 was Capital World Investors, an estimated $13.4M added.
- The largest Unity Biotechnology seller in Q3 2018 was EcoR1 Capital, an estimated $11.7M sold.
Based on aggregated 13F filings for Q3 2018.